Table 1.
Patient Characteristics
| Included in PET/CT study (n=74) | Eligible for PET/CT study but excluded (n=577) | |
|---|---|---|
| Assigned treatment, p=0.26 [1] | ||
| RT + cisplatin | 42 (56.8%) | 287 (49.7%) |
| RT + cisplatin + cetuximab | 32 (43.2%) | 290 (50.3%) |
| Age (years), p=1.00 [2] | ||
| Mean (standard deviation) | 56.8 (6.67) | 56.7 (8.22) |
| Median (range) | 56 (42–73) | 57 (34–79) |
| Gender, p=0.68 [1] | ||
| Male | 65 (87.8%) | 516 (89.4%) |
| Female | 9 (12.2%) | 61 (10.6%) |
| Zubrod performance status, p=0.03 [1] | ||
| 0 | 58 (78.4%) | 380 (65.9%) |
| 1 | 16 (21.6%) | 197 (34.1%) |
| Smoking history: pack-years, p=0.03 [2] | (n=54) | (n=512) |
| Mean (standard deviation) | 20.8 (29.88) | 26.1 (26.96) |
| Median (range) | 8.75 (0–135) | 21 (0–162) |
| Primary site, p=0.72 [1] | ||
| Oropharynx | 58 (78.4%) | 449 (77.8%) |
| Hypopharynx | 7 (9.5%) | 43 (7.5%) |
| Larynx | 9 (12.2%) | 85 (14.7%) |
| p16 status, oropharynx only, p=0.98 [1] | (n=33) | (n=229) |
| Negative | 8 (24.2%) | 55 (24.0%) |
| Positive | 25 (75.8%) | 174 (76.0%) |
| T stage, p=0.04 [2] | ||
| T2 | 29 (39.2%) | 303 (52.5%) |
| T3 | 26 (35.1%) | 157 (27.2%) |
| T4 | 19 (25.7%) | 117 (20.3%) |
| N stage, p=0.23 [2] | ||
| N2a | 5 (6.8%) | 73 (12.7%) |
| N2b | 34 (45.9%) | 259 (44.9%) |
| N2c | 29 (39.2%) | 207 (35.9%) |
| N3 | 6 (8.1%) | 38 (6.6%) |
[1]
Pearson chi-square test.
[2]
Wilcoxon rank-sum test.